Curis Reports Q3 2026 Results and Drug Trial Updates
Curis reported Q3 2026 results featuring operational highlights from emavusertib studies in CLL and PCNSL, showing promising response rates that may support regulatory filings.
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.
Get real-time financial news in your trading bot or app
START FREE — 10,000 calls/day, no key needed